All In Biotech

Drug Trial Radar · NCT03989947

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

A Phase 2 Open-Label Long-Term Extension Study to Evaluate the Safety and Efficacy of BMN 111 in Children With Achondroplasia

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

73

Actual

Start

Jun 12, 2019

Primary completion

May 2038

Study completion May 2038

Sponsor

Lead sponsor
BioMarin PharmaceuticalBioMarin (BMRN)
Sponsor type
Industry
First posted
Jun 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 15 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2, open-label multi-center long-term extension study, with approximately 70 subjects, to evaluate the safety and efficacy of BMN111 in children with Achondroplasia until subjects reach near-adult final height. Eligible subjects will have completed 1 year of BMN111 or placebo treatment in the 111-206 study and once enrolled in the 111-208 extension study will receive a daily dose of BMN111 by subcutaneous injection according to their age as determined by 111-206.

Conditions

  • Achondroplasia

Interventions

  • Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.Drug

    Modified recombinant human C-type natriuretic peptide (subject to adjustment per protocol)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: "Through study completion, an average of 5 years"
  2. Evaluate change in height/length z-score in children with ACH treated with BMN 111Time frame: "Through study completion, an average of 5 years"

Locations

16 sites in 4 countries. Site status is shown where the registry gives one.

  • Children's Hospital & Research Center Oakland

    Oakland, California

  • Harbor - UCLA Medical Center

    Torrance, California

  • Alfred I. duPont Hospital for Children

    Wilmington, Delaware

  • Emory University

    Decatur, Georgia

  • Ann Robert and H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Cincinnati Childrens Hospital

    Cincinnati, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Baylor College of Medicine

    Houston, Texas

  • Medical College of Wisconsin, Children's Hospital

    Milwaukee, Wisconsin

  • The Children's Hospital at Westmead

    Westmead, New South Wales, Australia

  • Murdoch Children's Research Institute

    Parkville, Victoria, Australia

  • Osaka University

    Osaka, Japan

  • Saitama Children's Medical Center

    Saitama, Japan

  • Tokushima University Hospital

    Tokushima, Japan

  • Guy's and St. Thomas NHS Foundation Trust Evelina Children's Hospital

    London, United Kingdom

  • Sheffield Children's NHS Foundation Trust

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.